tiprankstipranks
Advertisement
Advertisement

MX:JNJ Stock Latest News

Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital
The FlyProtagonist Therapeutics price target raised to $178 from $112 at BMO Capital
6d ago
JNJ
PTGX
Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition
PremiumThe Fly
Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition
6d ago
JNJ
ISRG
Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs
PremiumThe Fly
Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs
6d ago
JNJ
LEGN
Trump Trade: President signs EO to split up of childhood vaccines
PremiumThe Fly
Trump Trade: President signs EO to split up of childhood vaccines
12d ago
AZN
EBS
Trump signs EO to split up of childhood vaccines, Bloomberg reports
PremiumThe Fly
Trump signs EO to split up of childhood vaccines, Bloomberg reports
13d ago
AZN
EBS
Protagonist Therapeutics price target raised to $173 from $118 at Wedbush
PremiumThe FlyProtagonist Therapeutics price target raised to $173 from $118 at Wedbush
13d ago
JNJ
PTGX
Trump Trade: U.S. issues 15% duty on products made from polysilicon
Premium
The Fly
Trump Trade: U.S. issues 15% duty on products made from polysilicon
16d ago
AZN
EBS
Trump admin plans to issue executive order on vaccines, autism, Bloomberg says
Premium
The Fly
Trump admin plans to issue executive order on vaccines, autism, Bloomberg says
16d ago
AZN
EBS
Johnson & Johnson price target raised to $287 from $270 at Guggenheim
PremiumThe Fly
Johnson & Johnson price target raised to $287 from $270 at Guggenheim
17d ago
JNJ
Zymeworks price target raised to $51 from $46 at H.C. Wainwright
PremiumThe Fly
Zymeworks price target raised to $51 from $46 at H.C. Wainwright
18d ago
JNJ
JAZZ
JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target
PremiumRatings
JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target
19d ago
JNJ
Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target
PremiumRatings
Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target
19d ago
JNJ
Johnson & Johnson announces leadership change in Innovative Medicine
PremiumCompany AnnouncementsJohnson & Johnson announces leadership change in Innovative Medicine
19d ago
8K
JNJ
Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman
Premium
The Fly
Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman
19d ago
JNJ
Johnson & Johnson price target raised to $282 from $272 at Wells Fargo
Premium
The Fly
Johnson & Johnson price target raised to $282 from $272 at Wells Fargo
20d ago
JNJ
Johnson & Johnson removed from US Conviction List at Goldman Sachs
PremiumThe Fly
Johnson & Johnson removed from US Conviction List at Goldman Sachs
20d ago
JNJ
Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review
PremiumThe Fly
Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review
24d ago
JNJ
Johnson & Johnson Updates Guidance After Firefly, Sail Deals
PremiumCompany Announcements
Johnson & Johnson Updates Guidance After Firefly, Sail Deals
25d ago
8K
JNJ
Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36
PremiumThe Fly
Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36
25d ago
JNJ
JNJ enters strategic agreement to acquire Sail Biomedicines for $2.58B
PremiumThe FlyJNJ enters strategic agreement to acquire Sail Biomedicines for $2.58B
25d ago
JNJ
Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68
Premium
The Fly
Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68
25d ago
JNJ
Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B
Premium
The Fly
Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B
25d ago
JNJ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >